naphazoline has been researched along with Hypertension, Pulmonary in 3 studies
Naphazoline: An adrenergic vasoconstrictor agent used as a decongestant.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Carbone, RG | 1 |
| Monselise, A | 1 |
| Puppo, F | 1 |
| Lopes, LM | 1 |
| Carrilho, MC | 1 |
| Francisco, RP | 1 |
| Lopes, MA | 1 |
| Krebs, VL | 1 |
| Zugaib, M | 1 |
| Perrin, S | 1 |
| Montani, D | 1 |
| O'Connell, C | 1 |
| Günther, S | 1 |
| Girerd, B | 1 |
| Savale, L | 1 |
| Guignabert, C | 1 |
| Sitbon, O | 1 |
| Simonneau, G | 1 |
| Humbert, M | 1 |
| Chaumais, MC | 1 |
3 other studies available for naphazoline and Hypertension, Pulmonary
| Article | Year |
|---|---|
Treprostinil and Clinical Outcome in Pulmonary Hypertension and Interstitial Lung Disease: Is All Clear?
Topics: Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; | 2023 |
Fetal ductus arteriosus constriction and closure: analysis of the causes and perinatal outcome related to 45 consecutive cases.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Flow Velocity; Caffeine; Central N | 2016 |
Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Amphetamines; Case-Control Studies; Female; Humans; Hyperten | 2015 |